A股異動 | 愛爾眼科復牌漲逾6% 擬收購眼科醫院增至30家
格隆匯10月30日丨愛爾眼科(300015.SZ)復牌漲逾6%,報40.52元,股價再創上市以來新高,成交8.58億元,總市值1255億元。公司擬以發行股份方式購買萬州愛瑞陽光眼科醫院90%股權與開州愛瑞陽光眼科醫院90%股權。同時,上市公司擬向不超過5名特定投資者以發行股份方式募集配套資金,用於支付本次交易的現金對價、本次交易相關中介機構費用及補充上市公司流動資金。而在此前,愛爾眼科曾發佈公告,公司擬以發行股份方式購買天津中視信100%股權,由此間接收購愛爾產業基金的26家眼科醫院;擬以發行股份及支付現金方式購買奧理德視光100%股權與宣城眼科醫院80%股權。至此,公司擬收購眼科醫院增至30家。華鑫證券昨日發佈研報,預測公司2019-2021年實現歸屬於母公司淨利潤分別為13.58億元、17.77億元、22.57億元,維持“推薦”評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.